Sanofi hires Selexis SA for three cell line development deals

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Biotechnology, Cell culture

Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.

The deals – financial terms of which were not disclosed - will see Selecta develop cell lines for a complex recombinant vaccine protein, a bispecific antibody and so-called “naked” antibody lacking any drug element.

Development will utilize Selexis’ SUREtechnology which is used to insert genes into Chinese hamster ovary (CHO) cells and other mammalian cell lines used in biopharmaceutical production.

Robert Meister, head of Corporate Communications at Selexis SA, told us "This research will take place in Selexis’ new lab facility, formerly owned by Merck Serono, in Plan-les-Ouates, Switzerland."

"Selexis cannot disclose how long the work will take, but typically Selexis produces new research cell banks in approximately 14 weeks" he added.

Selexis has similar cell development and technology access deals with ImmuNext, Laboratorios Liomont, Progenics Pharmaceuticals, ASLAN Pharmaceuticals​ and Pieris Pharmaceuticals​.

News of the Sanofi contracts comes months​ after the firm told us it will begin a "major expansion"​ this year.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more